Your browser is no longer supported. Please, upgrade your browser.
Settings
STSA [NASD]
Satsuma Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.53 Insider Own9.90% Shs Outstand21.98M Perf Week-8.38%
Market Cap157.00M Forward P/E- EPS next Y-1.87 Insider Trans64.01% Shs Float15.49M Perf Month1.44%
Income-46.20M PEG- EPS next Q-0.41 Inst Own73.20% Short Float4.48% Perf Quarter-23.12%
Sales- P/S- EPS this Y-68.60% Inst Trans113.27% Short Ratio5.23 Perf Half Y1.44%
Book/sh6.29 P/B0.78 EPS next Y6.00% ROA-44.10% Target Price- Perf Year-82.85%
Cash/sh4.17 P/C1.18 EPS next 5Y- ROE-47.80% 52W Range3.50 - 36.10 Perf YTD6.72%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-86.37% Beta-
Dividend %- Quick Ratio25.50 Sales past 5Y- Gross Margin- 52W Low40.57% ATR0.29
Employees19 Current Ratio25.50 Sales Q/Q- Oper. Margin- RSI (14)40.64 Volatility5.86% 5.48%
OptionableYes Debt/Eq0.02 EPS Q/Q29.70% Profit Margin- Rel Volume0.79 Prev Close5.03
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume132.68K Price4.92
Recom2.70 SMA20-5.93% SMA50-5.65% SMA200-16.90% Volume104,456 Change-2.19%
Apr-26-21Resumed Credit Suisse Neutral $6.50
Mar-02-21Upgrade Credit Suisse Underperform → Neutral $6.50
Sep-11-20Downgrade SVB Leerink Outperform → Mkt Perform
Sep-11-20Downgrade Mizuho Buy → Neutral $32 → $4
Sep-11-20Downgrade Credit Suisse Outperform → Neutral $33 → $4
Jul-27-20Initiated H.C. Wainwright Buy $35
Feb-06-20Initiated Mizuho Buy
Oct-08-19Initiated SVB Leerink Outperform
Oct-08-19Initiated Credit Suisse Outperform $16
May-11-21 04:01PM  
May-10-21 09:28AM  
Mar-26-21 05:29AM  
Mar-25-21 05:00PM  
Mar-10-21 08:00AM  
Mar-01-21 08:43AM  
07:00AM  
07:00AM  
Feb-01-21 09:47AM  
Jan-25-21 08:57AM  
Jan-04-21 10:11AM  
Dec-28-20 10:16AM  
Dec-07-20 10:45PM  
Nov-24-20 04:16PM  
Nov-23-20 10:24AM  
Nov-10-20 04:02PM  
Nov-02-20 04:35PM  
Oct-06-20 06:09AM  
Sep-11-20 10:12AM  
08:05AM  
Sep-10-20 11:39AM  
08:00AM  
Sep-03-20 06:57PM  
Aug-12-20 01:55AM  
Aug-06-20 04:01PM  
Jul-27-20 09:33AM  
Jul-07-20 04:01PM  
Jun-11-20 04:05PM  
Jun-10-20 02:26PM  
Jun-01-20 04:05PM  
May-27-20 08:30AM  
May-18-20 04:05PM  
May-12-20 04:01PM  
Apr-28-20 04:05PM  
Mar-10-20 04:01PM  
Mar-05-20 04:01PM  
Feb-18-20 08:00AM  
Jan-28-20 04:05PM  
Dec-16-19 01:47PM  
Nov-26-19 07:00AM  
Nov-12-19 04:01PM  
Sep-20-19 08:00PM  
03:28PM  
Sep-17-19 04:01PM  
Sep-13-19 04:12PM  
Sep-12-19 07:30PM  
Sep-11-19 03:31PM  
Sep-03-19 08:00AM  
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorFeb 26Buy5.681,232,3946,999,9985,155,854Mar 02 04:30 PM
O'Neil Thomas P.Chief Financial OfficerSep 01Option Exercise4.567503,420750Sep 03 04:05 PM
ALBRECHT DETLEFChief Medical OfficerSep 01Option Exercise4.561,0004,56021,212Sep 03 04:06 PM
ALBRECHT DETLEFChief Medical OfficerSep 01Sale22.211,00022,21020,212Sep 03 04:06 PM
O'Neil Thomas P.Chief Financial OfficerSep 01Sale22.1975016,6450Sep 03 04:05 PM
O'Neil Thomas P.Chief Financial OfficerAug 05Option Exercise4.561,0004,5601,000Aug 07 06:40 PM
O'Neil Thomas P.Chief Financial OfficerAug 05Sale25.001,00025,0000Aug 07 06:40 PM
ALBRECHT DETLEFChief Medical OfficerAug 03Option Exercise4.561,0004,56021,012Aug 05 04:03 PM
ALBRECHT DETLEFChief Medical OfficerAug 03Sale22.911,00022,90620,212Aug 05 04:03 PM
ALBRECHT DETLEFChief Medical OfficerJul 01Option Exercise4.561,0004,56020,812Jul 02 04:13 PM
O'Neil Thomas P.Chief Financial OfficerJul 01Option Exercise4.561,0004,560394Jul 02 04:15 PM
O'Neil Thomas P.Chief Financial OfficerJul 01Sale26.651,00026,6540Jul 02 04:15 PM
ALBRECHT DETLEFChief Medical OfficerJul 01Sale26.681,00026,68320,212Jul 02 04:13 PM
O'Neil Thomas P.Chief Financial OfficerJun 23Option Exercise1.042,1152,2002,115Jun 24 04:53 PM
O'Neil Thomas P.Chief Financial OfficerJun 23Sale35.232,11574,5120Jun 24 04:53 PM